234 related articles for article (PubMed ID: 18613325)
21. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
Goo AK; Carson DS; Bjelajac A
J Fam Pract; 1996 Jun; 42(6):612-8. PubMed ID: 8656173
[TBL] [Abstract][Full Text] [Related]
22. Rational choice of oral antihyperglycaemic agents.
Chowdhury S; Sengupta N
J Indian Med Assoc; 2002 Mar; 100(3):174-5, 177. PubMed ID: 12408278
[TBL] [Abstract][Full Text] [Related]
23. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
Bosi E
Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
[TBL] [Abstract][Full Text] [Related]
24. Management of type 2 diabetes: long-awaited evidence of benefits after blood sugar control.
Prescrire Int; 1999 Oct; 8(43):147-52. PubMed ID: 11503841
[TBL] [Abstract][Full Text] [Related]
25. Strategies of the treatment of type II diabetes mellitus.
Mehra IV
Pharm Pract Manag Q; 1997 Jul; 17(2):1-11. PubMed ID: 10168173
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
Ong CR; Molyneaux LM; Constantino MI; Twigg SM; Yue DK
Diabetes Care; 2006 Nov; 29(11):2361-4. PubMed ID: 17065668
[TBL] [Abstract][Full Text] [Related]
27. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
Scheen AJ; Paquot N; Lefebvre PJ
Rev Med Liege; 2008 Oct; 63(10):624-9. PubMed ID: 19009971
[TBL] [Abstract][Full Text] [Related]
28. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.
Wiernsperger NF; Bailey CJ
Drugs; 1999; 58 Suppl 1():31-9; discussion 75-82. PubMed ID: 10576523
[TBL] [Abstract][Full Text] [Related]
29. Metformin--an update.
Bailey CJ
Gen Pharmacol; 1993 Nov; 24(6):1299-309. PubMed ID: 8112499
[TBL] [Abstract][Full Text] [Related]
30. Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors.
Lebovitz HE
Drugs; 1992; 44 Suppl 3():21-8. PubMed ID: 1280574
[TBL] [Abstract][Full Text] [Related]
31. [++UKPDS Study. Metformin in obese patients with Type 2 diabetes (UKPDS 340].
Janka HU
Internist (Berl); 2000 Jul; 41(7):688-9. PubMed ID: 10929259
[No Abstract] [Full Text] [Related]
32. Metformin: New Preparations and Nonglycemic Benefits.
Fujita Y; Inagaki N
Curr Diab Rep; 2017 Jan; 17(1):5. PubMed ID: 28116648
[TBL] [Abstract][Full Text] [Related]
33. Prevention of type 2 diabetes: role of metformin.
Charles MA; Eschwège E
Drugs; 1999; 58 Suppl 1():71-3; discussion 75-82. PubMed ID: 10576529
[TBL] [Abstract][Full Text] [Related]
34. [Metformin and type 2 diabetes: the UKPDS experience].
Leverve XM
Journ Annu Diabetol Hotel Dieu; 2007; ():5-11. PubMed ID: 18610755
[No Abstract] [Full Text] [Related]
35. Beneficial effects of metformin on haemostasis and vascular function in man.
Grant PJ
Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S44-52. PubMed ID: 14502100
[TBL] [Abstract][Full Text] [Related]
36. New insights into the anti-diabetic actions of metformin: from the liver to the gut.
Wu T; Horowitz M; Rayner CK
Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):157-166. PubMed ID: 27983877
[TBL] [Abstract][Full Text] [Related]
37. Biguanides and NIDDM.
Bailey CJ
Diabetes Care; 1992 Jun; 15(6):755-72. PubMed ID: 1600835
[TBL] [Abstract][Full Text] [Related]
38. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.
Anfossi G; Russo I; Bonomo K; Trovati M
Curr Vasc Pharmacol; 2010 May; 8(3):327-37. PubMed ID: 19485923
[TBL] [Abstract][Full Text] [Related]
39. METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
Anabtawi A; Miles JM
Endocr Pract; 2016 Aug; 22(8):999-1007. PubMed ID: 27579542
[TBL] [Abstract][Full Text] [Related]
40. Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?
Khunti K; Seidu S; Davies MJ
Diabetes Obes Metab; 2019 Feb; 21(2):207-209. PubMed ID: 30178516
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
